IL2 and Miyoshi myopathy: Similarly, refractory and relapse of patients with MM treated with CS1-BCMA CAR-T exhibited an 81% ORR, with 6 cases achieving stringent complete response (sCR).34 Moreover, diversified manufacturing strategies, such as incorporating IL-2, enriching memory-like phenotype T-cells, and employing dual targeting, enhance CAR-T therapy outcomes.35,36 Although patients with MM treated with CAR-T therapy exhibit a high primary response rate, the early high relapse rate remains a challenge.